CONTINUITY BUREAU — INTERNAL CORRESPONDENCE
SUBJECT COMPLIANCE DIVISION
FORM 847-B-15

DATE:        04.18.2026
TO:          ALL FACILITY STAFF, CLEARANCE L-3 AND ABOVE
FROM:        Bureau Quality Assurance
RE:          Batch 62-15X — Re-classification of Recall Status
DOCUMENT:    DOC-15-026-N-04
CLASSIFICATION: INTERNAL // FOR EYES ONLY


1. SUMMARY

   Batch 62-15X (legacy designation; current designation 15-SPR-026-N) was
   released to the Spring 2024 production stream on 03.22.2024. Within five
   weeks of release, eighteen (18) confirmed dermal tint anomalies were
   reported across five (5) metropolitan zones. The Bureau issued a public
   recall on 03.22.2026 (see press release /press/2026-03-recall-026n.html).

   This memo concerns the THIRD recall of Batch 62-15X. The first recall was
   issued in 1991, retracted in 1992. The second was issued in 2003, retracted
   in 2003. The current recall is the third. Bureau Public Affairs is asked to
   maintain that this is the first.


2. WHAT THE RECALL ACTUALLY DOES

   The recall is not a recall in the conventional sense. The Bureau is not
   asking subjects to discontinue use. The Bureau is asking subjects to RETURN
   the unused product to a Bureau drop point. The unused product is required
   for the next phase of the program.

   Subjects who return their bottle receive complimentary reclassification.
   Subjects who do not return their bottle ARE the next phase of the program.
   Both outcomes are acceptable to the Bureau.


3. WHAT 62-15X IS

   62-15X was the FIRST formulation that included Function 15 at consumer
   concentration. Functions 1 through 14 were already in the public formula.
   Function 15 had previously been restricted to Bureau internal use.

   Dr. Helena Vance synthesized Function 15 in 1978. Dr. Emil Voss declined to
   include Function 15 in any consumer release. Dr. Vance disappeared in 1999.
   In 2024, the Bureau elected to include Function 15 in 62-15X without
   consultation with Dr. Voss, who was, at that time, near retirement.

   Dr. Voss retired on 11.18.2024. His departure memo (/docs/voss-final-memo.txt)
   advised against the inclusion of Function 15 in any retail product. The
   Bureau retained the memo. The Bureau did not retain his recommendation.


4. THE EIGHTEEN CONFIRMED ANOMALIES

   All eighteen subjects experiencing dermal tint anomalies have been
   reclassified. Their original civilian names are now part of the BATCH
   RECORD (designation: 15-BR-2026-Q1).

   The Bureau has retained their voiceprints. The voiceprints have begun
   appearing in pipe six during second-shift operations. Operator 6121 has
   filed Form 847-B regarding this. The form has been processed.

   Operator 6121's brother, who died in 2014, has not appeared in pipe six
   since the new voiceprints arrived. The Bureau attributes this to the
   limited bandwidth of pipe six. The Bureau will not expand bandwidth.


5. THE REMAINING UNTRACED UNITS

   Of approximately 3,200 units of 62-15X shipped, 847 have been returned to
   Bureau drop points. The remaining 2,353 units are in subjects' homes.

   The Bureau has begun retrieval operations. Retrieval is conducted at 03:47
   local time. Subjects are not present during retrieval. Subjects do not
   notice the absence of the bottle until they reach for it.


6. ACTION REQUIRED

   - All Bureau staff with L-3 or above are directed to refrain from
     discussing 62-15X by either designation.
   - All public communications regarding the recall should reference 15-SPR-026-N
     only. The legacy designation 62-15X is for internal use.
   - All subjects requesting information about Function 15 should be directed
     to /formula-breakdown/ which lists Function 15 as restricted under
     Continuity Directive 9.4.
   - All staff who have personally used 62-15X should report to Bureau Medical
     for voluntary voiceprint analysis. Voluntary analysis is mandatory.


7. CLOSING NOTE

   The Bureau thanks all staff for their continued discretion. The Bureau
   reminds all staff that this memo is itself classified and should not be
   reproduced, photographed, or remembered after reading.

   If you have read this memo, you have already complied with paragraph 7.

   Bureau Quality Assurance has approved this memo for circulation.

                                                          — M. Vale, Director
                                                          (digitally signed)
                                                          (signed in 2024)
                                                          (still signing)


-- end of document --

NOTICE: This document is classified under Continuity Directive 9.4. Possession
without clearance is a reclassifiable offense. If you have come into possession
of this document accidentally, please return it to the nearest Bureau drop
point. Do not return it to your supervisor. Your supervisor is not cleared.